Particularly, we were able to demonstrate the structure-dependent toxicity of PAs in PHH with a similar potency ranking as observed in metabolically competent liver cancer cell lines (i.e., HepG2-CYP3A4 and HepaRG). The gene discussed is CYP3A4; the disease is liver cancer.